Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKD1 | Q15139 | 2/20 | 0.46 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.45 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.42 |
| ▸ | GRM4 | Q14833 | 7/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | ULK1 | O75385 | 1/20 | 0.36 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3775905 | 0.82 | LRRK2 (0.46) | LRRK2GRM4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL19566588 | 0.80 | PRKD1 (0.34) | PRKD1PIP4K2APIP4K2CTGFBR1PIK3CA | |
| SCHEMBL13060922 | 0.79 | MAPT (0.45) | LRRK2GRM4LMNANPC1RAB9A | |
| SCHEMBL3775844 | 0.79 | ADRA2A (0.50) | LRRK2 | |
| SCHEMBL3770441 | 0.78 | GRM4 (0.61) | TGFBR1LRRK2GRM4LMNANPC1 | |
| SCHEMBL3769990 | 0.78 | LRRK2 (0.42) | LRRK2GRM4NPC1RAB9A | |
| SCHEMBL3775329 | 0.77 | LRRK2 (0.61) | LRRK2GRM4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3769220 | 0.77 | LRRK2 (0.70) | PRKD1TGFBR1LRRK2GRM4 | |
| SCHEMBL3762265 | 0.77 | GRM4 (0.54) | LRRK2GRM4 | |
| SCHEMBL3768341 | 0.75 | GRM4 (0.59) | LRRK2GRM4NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| EP-2408772-B1 | COMPOUNDS | MEDICAL RES COUNCIL TECHNOLOGY (GB) | 2015-07-01 | — | — | EP | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320870-A1 | COMPOUNDS | CBR3, CNR1, HCAR3 | PRKD1 3643/4885PIP4K2A 3436/4885PIP4K2C 3162/4885 |
| US-20100317646-A1 | COMPOUNDS | CBR3, CNR1, HCAR3 | PRKD1 3639/4885PIP4K2A 3403/4885PIP4K2C 3143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.